CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.
复制标题
DOI：
10.1016/j.molmed.2017.03.002
复制
发表时间：
2017-05
影响因子：
13.6
通讯作者：
Chen YY
中科院分区：
文献类型：
--
作者：
Chang ZL;Chen YY
嵌合抗原受体（汽车）是为T细胞提供工程化特异性的通用合成受体。在治疗B细胞恶性肿瘤方面的临床成功已经证明了CAR-T细胞对癌症的治疗潜力，并且正在努力将工程化T细胞的使用扩展到治疗各种医学疾病，包括感染和自身免疫性疾病。在这里，我们回顾了目前对汽车分子特性的理解，这些知识如何为新型受体的合理设计和表征提供信息，CAR-T细胞在临床上的成功和缺点，以及不断改进CAR-T细胞治疗的新兴解决方案。
Chimeric antigen receptors (CARs) are versatile synthetic receptors that provide T cells with engineered specificity. Clinical success in treating B-cell malignancies has demonstrated the therapeutic potential of CAR-T cells against cancer, and efforts are underway to expand the use of engineered T cells to the treatment of diverse medical conditions, including infections and autoimmune diseases. Here, we review current understanding of the molecular properties of CARs, how this knowledge informs the rational design and characterization of novel receptors, successes and shortcomings of CAR-T cells in the clinic, and emerging solutions for the continued improvement of CAR-T cell therapy.